Vidaza Disease Interactions
There are 4 disease interactions with Vidaza (azacitidine).
Azacitidine (applies to Vidaza) hepatic tumors
Major Potential Hazard, Moderate plausibility.
The use of azacitidine injection is contraindicated in patients with advanced malignant hepatic tumors.
References (1)
- (2004) "Product Information. Vidaza (azacitidine)." Celgene Corporation
Azacitidine (applies to Vidaza) hepatic impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
Azacitidine is potentially hepatotoxic in patients with preexisting hepatic impairment and caution should be exercised when prescribing in patients with liver disease.
References (1)
- (2004) "Product Information. Vidaza (azacitidine)." Celgene Corporation
Azacitidine (applies to Vidaza) renal impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction
Patients with renal impairment may be at increased risk of renal toxicity when using azacitidine. This drug is primarily excreted by the kidneys. Therefore, these patients should be closely monitored for toxicity.
References (1)
- (2004) "Product Information. Vidaza (azacitidine)." Celgene Corporation
Miscellaneous antineoplastics (applies to Vidaza) anemia
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Neutropenia, Thrombocytopenia
Some miscellaneous antineoplastics such as azacitidine and lenalidomide cause anemia, neutropenia, and thrombocytopenia. Patients with these preexisting conditions should be monitored carefully. Monitor complete blood counts frequently for response and/or toxicity, at a minimum, prior to each dosing cycle.
References (2)
- (2004) "Product Information. Vidaza (azacitidine)." Celgene Corporation
- (2006) "Product Information. Revlimid (lenalidomide)." Celgene Corporation
Switch to consumer interaction data
Vidaza drug interactions
There are 180 drug interactions with Vidaza (azacitidine).
Report options
More about Vidaza (azacitidine)
- Vidaza consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (13)
- Side effects
- Dosage information
- During pregnancy
- Generic availability
- FDA approval history
- Drug class: miscellaneous antineoplastics
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Reblozyl
Reblozyl is used to treat anemia in adults with beta-thalassemia or myelodysplastic syndromes ...
Tibsovo
Tibsovo (ivosidenib) is a once-daily oral medication that targets a specific gene mutation called ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Dacogen
Dacogen (decitabine) is used to treat myelodysplastic syndromes (certain types of blood or bone ...
Inqovi
Inqovi (decitabine and cedazuridine) is used for the treatment of myelodysplastic syndromes (MDS) ...
Rytelo
Rytelo (imetelstat) is an injectable telomerase inhibitor that may be used to treat adults with ...
Onureg
Onureg (azacitidine) is used for the continued treatment of adult patients with acute myeloid ...
Decitabine
Decitabine systemic is used for acute myeloid leukemia, myelodysplastic syndrome
Ivosidenib
Ivosidenib systemic is used for acute myeloid leukemia, biliary tract tumor, myelodysplastic syndrome
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.